Sorafenib Combined with Chemotherapy and Donor Lymphocyte Infusion As Salvage Therapy in Patients with FLT3-positive Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

L Xuan,Z P Fan,Y Zhang,N Xu,J Y Ye,X Zhou,Z X Wang,J Sun,Q F Liu,F Huang

DOI: https://doi.org/10.3760/cma.j.issn.0578-1426.2018.05.009

2018-01-01

Abstract:To explore the efficacy of sorafenib combined with chemotherapy and donor lymphocyte infusion (DLI) in patients with FLT3-positive acute myeloid leukemia (AML) relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Of the 14 patients relapsed after allo-HSCT,9 achieved complete remission after salvage therapy of sorafenib combined with chemotherapy and DLI,6 with complete molecular remission,2 with partial remission,and 3 with no response.With a median follow up of 220 (range,30-1 782) days after post-transplantation relapse,7 patients were still alive and 7 died.Salvage therapy of sorafenib combined with chemotherapy and DLI shows a decent therapeutic effect for FLT3-positive AML relapsed after allo-HSCT.